Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report)'s stock price shot up 1.1% during trading on Tuesday . The stock traded as high as $4.17 and last traded at $4.15. 1,204 shares traded hands during trading, a decline of 92% from the average session volume of 15,564 shares. The stock had previously closed at $4.10.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on NBTX shares. Guggenheim decreased their target price on shares of Nanobiotix from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, April 4th. UBS Group upgraded Nanobiotix to a "hold" rating in a research note on Monday, February 17th.
View Our Latest Stock Report on NBTX
Nanobiotix Stock Up 0.7%
The business has a 50 day moving average price of $3.53 and a 200 day moving average price of $3.43.
Institutional Trading of Nanobiotix
A number of institutional investors and hedge funds have recently bought and sold shares of NBTX. Geode Capital Management LLC bought a new position in shares of Nanobiotix in the fourth quarter worth approximately $29,000. Millennium Management LLC purchased a new position in Nanobiotix in the 4th quarter worth approximately $39,000. Jane Street Group LLC purchased a new position in Nanobiotix in the 4th quarter worth approximately $73,000. Finally, OLD Mission Capital LLC bought a new position in Nanobiotix in the 4th quarter valued at approximately $139,000. 38.81% of the stock is currently owned by institutional investors.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
See Also
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
